TFBS BioscienceROCO:6939 -0.48%49 Gross Margin % is 15.03% as of Dec. 2025, which is 52% below its 10-year median of 31.36. GuruFocus rates ROCO:6939 with a GF Score™ of 49/100 and a GF Value™ of NT$32.17 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 195 Medical Diagnostics & Research companies, TFBS Bioscience ranks worse than 89.23% on this metric.
TFBS Bioscience Inc gross margin has been in long-term decline. The average rate of decline per year is -10.2%.
The historical rank and industry rank for TFBS Bioscience's Gross Margin % or its related term are showing as below:
ROCO:6939'
s Gross Margin % Range Over the Past 10 Years
Min: 19.06 Med: 31.36 Max: 41.17
Current: 19.06
During the past 6 years, the highestGross Margin % of TFBS Bioscience was 41.17%. The lowest was 19.06%. And the median was 31.36%.
ROCO:6939's Gross Margin % is ranked worse than 89.23% of 195
companies
in the Medical Diagnostics & Research industry
Industry Median: 50.97
vs ROCO:6939: 19.06
TFBS Bioscience had a gross margin of 15.03% for the quarter that ended in Dec. 2025 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for TFBS Bioscience was -10.20% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
TFBS Bioscience had a gross margin of 15.03% for the quarter that ended in Dec. 2025 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
TFBS Bioscience Gross Margin % Related Terms
TFBS Bioscience Gross Margin % Historical Data
* Premium members only.
The historical data trend for TFBS Bioscience's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6939 vs TMO, DHR, IDXX: Gross Margin % Comparison
For the Diagnostics & Research subindustry, TFBS Bioscience's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TFBS Bioscience Gross Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, TFBS Bioscience's Gross Margin % distribution charts can be found below:
* The bar in red indicates where TFBS Bioscience's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
TFBS Bioscience (ROCO:6939) has a Gross Margin % of 15.03% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on TFBS Bioscience and its competitors. This is 52% below median its historical median of 31.36. Over the past decade, TFBS Bioscience's Gross Margin % has ranged from 19.06 to 41.17. According to the industry distribution chart, TFBS Bioscience ranks #174 out of 195 companies in the Medical Diagnostics & Research industry, placing it in the top 89.2%.
Is TFBS Bioscience's Gross Margin % too high?
TFBS Bioscience's current Gross Margin % of 15.03% is 52% below median its 10-year median of 31.36. Over the past 10 years, this metric has ranged from a low of 19.06 to a high of 41.17. The Medical Diagnostics & Research industry median Gross Margin % is 50.97. TFBS Bioscience's value of 15.03% is 70.5% below this industry median. Based on the distribution chart, TFBS Bioscience ranks #174 out of 195 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, TFBS Bioscience has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does TFBS Bioscience's Gross Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, TFBS Bioscience ranks #174 out of 195 companies for Gross Margin %. This places TFBS Bioscience in the lower half of its industry. The industry median Gross Margin % is 50.97. TFBS Bioscience's value of 15.03% is 70.5% below this benchmark. Historically, TFBS Bioscience's own Gross Margin % has ranged from 19.06 to 41.17 over the past decade. While the company's 10-year median is 31.36 vs. the industry median of 50.97, TFBS Bioscience has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Diagnostics & Research company?
The median Gross Margin % among Medical Diagnostics & Research companies is 50.97, based on 195 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TFBS Bioscience's current Gross Margin % of 15.03% is 70.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on TFBS Bioscience and its competitors. For the Medical Diagnostics & Research industry, the median Gross Margin % is 50.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TFBS Bioscience's current Gross Margin % is 15.03%, which is 52% below median its own 10-year median of 31.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TFBS Bioscience stock overvalued right now?
Based on GuruFocus' analysis, TFBS Bioscience (ROCO:6939) is currently considered Possible Value Trap. The stock's GF Value™ is NT$32.17, compared to a current price of NT$20.60 — trading 36% below its estimated fair value. The current Gross Margin % is 15.03%, which is 52% below median its 10-year median of 31.36 and 70.5% below the Medical Diagnostics & Research industry median of 50.97. TFBS Bioscience's overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For TFBS Bioscience (ROCO:6939), the current Gross Margin % is 15.03% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TFBS Bioscience (ROCO:6939) Overvalued in 2026?
Based on GuruFocus' analysis, TFBS Bioscience stock appears to be undervalued.
The current stock price of NT$20.60 is trading 36% below its estimated GF Value™ of NT$32.17.
GuruFocus considers TFBS Bioscience to be Possible Value Trap.
Key valuation signals for ROCO:6939:
Gross Margin %: 15.03% (52% below median its 10-year median of 31.36)
GF Value™: NT$32.17 vs. price of NT$20.60 (36% below fair value)
Industry Position: 70.5% below the Medical Diagnostics & Research median (#174 of 195)
No single metric tells the full story. See the ROCO:6939 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TFBS Bioscience Inc is a Contract Research Organization (CRO) providing biological testing in Taiwan. Its services include viral vector manufacturing for cell and gene therapy products and biosafety testing and product release testing for cell and gene therapy products, vaccines, and biologic products.
49GF Score
Get the complete analysis for ROCO:6939
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6939 has been successfully added to your 
